Q-omics provides the consensus-scored SNX20 profile across patient tissues and cancer cell-line models. SNX20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SNX20 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SNX20 RNA expression shows 22,355 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where SNX20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX20 survival associations across molecular data types. SNX20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX20 RNA expression–survival associations across cancer types. High SNX20 expression shows unfavorable associations in LGG and UVM, but favorable associations in HNSC, SKCM, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SNX20 RNA expression.
This table summarizes SNX20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SNX20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX20 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and BRCA. The KIRC box plot shows higher SNX20 RNA expression in tumor versus normal tissue (log2 FC = +1.882, t-test p < 0.001).
This table shows molecular features associated with SNX20 in patient tissues and cancer cell lines. In patient samples, SNX20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
